Page last updated: 2024-08-26

bosentan anhydrous and Anterior Ischemic Optic Neuropathy

bosentan anhydrous has been researched along with Anterior Ischemic Optic Neuropathy in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chiquet, C; Flet, L; Gohier, P; Heron, E; Lehmann, A; Milea, D; Pepin, JL; Quesada, JL; Rougier, MB; Roustit, M; Thuret, G; Vignal, C	1

Trials

1 trial(s) available for bosentan anhydrous and Anterior Ischemic Optic Neuropathy

Article	Year
Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol. Trials, 2022, Oct-29, Volume: 23, Issue:1 Topics: Bosentan; Clinical Trials, Phase III as Topic; Endothelin Receptor Antagonists; Humans; Middle Aged; Multicenter Studies as Topic; Optic Neuropathy, Ischemic; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Endothelin; Retinal Ganglion Cells; Tomography, Optical Coherence	2022

Article

Year

Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol.

Trials, 2022, Oct-29, Volume: 23, Issue:1

Topics: Bosentan; Clinical Trials, Phase III as Topic; Endothelin Receptor Antagonists; Humans; Middle Aged; Multicenter Studies as Topic; Optic Neuropathy, Ischemic; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Endothelin; Retinal Ganglion Cells; Tomography, Optical Coherence

2022